ArticleCureus2025
Ovarian Rhabdomyosarcoma in Children.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRhabdomyosarcoma is the most common soft tissue sarcoma in children. It predominantly arises in parameningeal and periorbital regions, as well as in other areas that do not typically contain striated muscle. Ovarian involvement is rare and may be attributed to the presence of ovarian stromal fibroblasts, or endometriotic stroma. Ovaries may be considered a favorable site for rhabdomyosarcoma. The disease typically presents in children under three years of age, often at an advanced stage and with nonspecific symptoms. Management requires a multimodal treatment approach.
methodsThis was a retrospective analysis of ovarian rhabdomyosarcoma cases over the past 25 years at a national cancer referral center in Peru.
resultsSix female patients, aged between five months and 13 years, were included in the study. Four of them were classified as clinical stage and group IV due to the presence of distant metastases, while the remaining two were categorized as low-risk. The majority had embryonal histology, and none tested positive for fusion genes. All patients underwent chemotherapy and surgery. Surgical approaches varied according to disease extent, with an emphasis on fertility preservation. These ranged from unilateral adnexectomy with ovarian-sparing staging in cases of suspected localized disease, to primary cytoreduction without hysterectomy or contralateral adnexectomy in cases presenting with severe symptoms due to mass effect from advanced tumors. Chemotherapy regimens were selected based on risk stratification and aligned with international treatment protocols. Three patients received intensity-modulated abdominopelvic radiotherapy at a total dose of 2,400 cGy, delivered in 16 sessions for peritoneal sarcomatosis, two due to persistent disease following chemotherapy and surgery, and one due to high-risk histology. One low-risk patient achieved a survival of up to 94 months.
conclusionsOvarian rhabdomyosarcoma is rare. Its clinical and radiological manifestations are nonspecific. The use of immunohistochemistry is essential for diagnosis. Advanced disease with embryonal histology is predominantly observed. Multimodal treatment has achieved survival exceeding 87 months even in cases of metastatic stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.